References

  1. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004; 350: 233542. PubMed | Google Scholar

  2. Kabbinavar FF, Hambleton J, Mass RD, Hurwitz HI, Bergsland E, Sarkar S. Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol. 2005; 23: 370612. PubMed | Google Scholar

  3. Giantonio BJ, Catalano NJ, Meropol NJ, O'Dwyer PJ et al. High-dose bevacizumab improves survival when combined with FOLFOX4 in previously treated advanced colorectal cancer: results from the Eastern Cooperative Oncology Group( ECOG ) study E3200, Abstract. J Clin Oncol. 2005; 23: S2. PubMed | Google Scholar

  4. Gordon MS, Cunningham D. Managing patients treated with bevacizumab combination therapy. Oncology. 2005; 69 (Suppl 3): 2533. PubMed | Google Scholar

  5. Saif MW, Mehra R. Incidence and management of bevacizumab- related toxicities in colorectal cancer. Expert Opin Drug Saf. 2006; 5: 55366. PubMed | Google Scholar